New Industries Require New Insight 

The microbiome and its role in human health represents a paradigm shift in how medicines will be developed. The PRI was founded to make Microbiotic Medicinal Products a therapeutic reality in Europe.

Learn More

A Unique Collaborative Approach

The PRI, as a neutral and financially independent non-profit association, applies a unique collaborative approach to improve market access and provide technical and regulatory intelligence for its members.

Our Strategy

The Future of Human Health

The PRI believes that the microbiome is the future of human medicine. Our members have a stake in regulatory, technical and collaboration efforts of the microbiome & human health space. 

Our Members

Board of Directors

President

Yakult Europe

Bruno Pot

Yakult Europe

First Vice President

YSOPIA Bioscience

Sandrine Claus

YSOPIA Bioscience

Second Vice President

Chr. Hansen

Charlotte Hemmingsen

Chr. Hansen

Secretary

5QBD Biotech

Frédérique Vieville

5QBD Biotech

Treasurer

Nexbiome Therapeutics

Stanislas Desjonquères

Nexbiome Therapeutics

Board Member

Accelsiors CRO

Jelena Cvejic

Accelsiors CRO
ADM Protexin

Ana Enriquez

ADM Protexin
Astel Medica

Nail Nasir

Astel Medica
Bioaster

Vincent Thomas

Bioaster
BioGaia AB

Gianfranco Grompone

BioGaia AB
Caelus Health

Luc Sterkman

Caelus Health
Ferring Pharmaceuticals

Michelle Carr

Ferring Pharmaceuticals

Board of Directors

Johnson & Johnson

Katarina Lundh

Johnson & Johnson
Labskin UK

Éile Butler

Labskin UK
Lallemand Health Solutions

Sylvie Binda

Lallemand Health Solutions
MaaT Pharma

Eugenio Fernandez

MaaT Pharma
MRM Health

Selin Bolca

MRM Health
POSTECH

Sin-Hyeog Im

POSTECH
Probiotical

Marco Pane

Probiotical
TargEDys

Grégory Lambert

TargEDys
University Clermont-Auvergne (UCA)

Monique Alric

University Clermont-Auvergne (UCA)
VetAgro Sup

Laurent Rios

VetAgro Sup
YUN Probiotherapy

Ingmar Claes

YUN Probiotherapy

Meet the Team

Magali

Magali

Scientific & Regulatory Affairs Director
Céline

Céline

Microbiome Project Manager
Joseph

Joseph

Operations Manager
Nick

Nick

Pharmabiotics Event Director

Our Members

Start Ups

Start Ups

Biotechs

Biotechs

Investors

Investors

CROs

CROs

Research Institutions

Research Institutions

LBP Developers

LBP Developers

CDMOs

CDMOs

Pharma

Pharma

Our current Members

Membership in the PRI plays an important role in several of our members’ development & marketing strategies. 

Intelligence

Intelligence

Development Planning

Development Planning

Networking

Networking

Scientific Foresight

Scientific Foresight

Investment

Investment

Membership Packages

What are Microbiotic Medicinal Products (MMPs)?

The PRI defines MMPs as any medicinal product containing living, dead or fragments…, of components of the microbiome (i.e. bacteria, yeasts, phages, etc…) with the purpose to prevent or treat human diseases through a pharmacological, microbiological, neurological, immunological or metabolic mode of action, or make a medical diagnosis.

PRI
Non-Living Cells

Non-Living Cells

Live Biotherapeutic Products

Live Biotherapeutic Products

Faeces-derived Rx

Faeces-derived Rx

Phage Therapy

Phage Therapy

Non-profit Association (loi 1901) | Europe’s first Microbiome Regulatory Science Expertise Center whose mission is to clarify and confirm the specific requirements for the development of microbiome-based medicinal products.

FIND OUT MORE
Expertise

Expertise

Patients/Health

Patients/Health

Medicine

Medicine

Synergy

Synergy

Find out more about the PRI from some of her members…

Bruno Pot

Peter Cartwright

Stanislas Desjonquères

Nina Vinot

“…I am deeply convinced that if we grow our microbiotic medicinal products business, all companies and universities and academics should gather to create a new kind of offer to better treat patients.” Stanislas Desjonquères

“We had been thinking for sometime that the regulatory structure of probiotics was not satisfactory – probiotics had evolved from fermented foods – but really it fits more comfortably in the medicinal sector.” Peter Cartwright

“…for a Pharma company like Ferring, we really understand and think that next step will be developing Pharmabiotics in a true ‘Pharma’ way, and the PRI is in our opinion is the key partner and leader in Europe.” Jaimé Lopez

Magali Cordaillat-Simmons

Marco Pané

“The possibility to link up the academic world as well as the industry world in the PRI is really a very interesting option.” Bruno Pot

“…I’m really glad to be a part of these Task Groups – at the moment the PRI activities indeed for our company is something really relevant.” Marco Pané

Etienne Nouguez

“Probiotical has been with the PRI since the very beginning – and we’re very happy about our investment, as it is more and more important for developing Live Biotherapeutic Products.” Nina Vinot

“We are interested in the way the PRI is working with industrials, academics and Regulatory bodies to construct this market for pharmabiotics.” Etienne Nouguez

“…in fact the European aspect grew and grew for the PRI…an association that began with French roots has now become a truly European organization.” Massimo Marzorati 

Massimo Marzorati

Jaimé Lopez

PRI
PRI
PRI

One-to-One Partnering

Microbiome dedicated one-to-one partnering forum. Schedule 20+ meetings with decision makers from Academia & Industry.

Conference

30+ presentations covering topics such as Cancer, Gut-Lung Axis, Urogenital as well as Regulatory Affairs and Market Trends.

Exhibition

Tailor suited solutions for your business needs. Promote your products and services to the Global Microbiome Community.

Innovation Showcase

Start-ups, spin-offs, academics & entrepreneurs present the latest innovations of microbiome products, services and research.

PRI
Find out more

Latest Updates

Our Blog

EMA & FDA apply a similar mindset when providing scientific advice for Live Biotherapeutic Product development

EMA & FDA apply a similar mindset when providing scientific advice for Live Biotherapeutic Product development

Open Letter to PRI Members – Fall 2020

Open Letter to PRI Members – Fall 2020

New live biotherapeutics will require regulatory and scientific innovation: the importance of a defined regulatory framework

New live biotherapeutics will require regulatory and scientific innovation: the importance of a defined regulatory framework

Live Biotherapeutic Products and Safety Assessment

Live Biotherapeutic Products and Safety Assessment

Open Letter to PRI Members – Winter 2019

Open Letter to PRI Members – Winter 2019

Addressing the Unique Challenges of Live Biotherapeutic Products when Designing Clinical Trials

Addressing the Unique Challenges of Live Biotherapeutic Products when Designing Clinical Trials

IMM-ETG: A New European Initiative for Intestinal Microbiome Medicinal Products

IMM-ETG: A New European Initiative for Intestinal Microbiome Medicinal Products

Open Letter to PRI Members – Spring 2019

Open Letter to PRI Members – Spring 2019

Contact Us

Our team is available to answer any questions you may have. Please contact us by phone or email us directly. 

Send us a message: